EIK1005-002: A Clinical Research Study Evaluating EIK1005, a Werner Helicase Inhibitor, as Monotherapy and in Combination With Pembrolizumab in Participants With Advanced Solid Tumors Including Microsatellite Instability High (MSI-H) Tumors
This is not medical advice. AI-assisted translation — inaccuracies may occur. Always verify the original and consult your oncologist before taking any steps.
About the trial
The goal of this clinical trial is to determine the most effective dose of EIK1005 that a person can take safely. Additionally, this study will test how well EIK1005 is tolerated alone and in combination with pembrolizumab in treating patients with advanced cancer.
Original English text from ClinicalTrials.gov
Who can (and can't) join
✓ Qualifies
- •Wiek co najmniej 18 lat
- •Spodziewana długość życia co najmniej 3 miesiące
- •Potwierdzony zaawansowany rak litych tkanek (nieoperacyjny lub z przerzutami)
- •Poprzednie leczenie zaawansowanego raka, które nie zadziałało lub było źle tolerowane
- •Mierzalne zmiany guza na badaniach obrazowych
- •Dobry ogólny stan zdrowia (ECOG 0-1)
- •Prawidłowa funkcja narządów wewnętrznych (wątroba, nerki, szpik kostny)
✗ Disqualifies
- •Utrzymujące się ciężkie skutki uboczne z poprzedniego leczenia raka
- •Poprzednie leczenie inhibitorami Werner helikazy
- •Uczulenie lub poważna alergia na składniki leku
- •Zaburzenia odporności lub przyjmowanie leków immunosupresyjnych (w częściach 1B i 2)
Simplified criteria — AI translation
Trial details
- Minimum age
- 18 Years
- Last updated (source)
- September 22, 2026
- Sex
- No restrictions
Therapies / drugs in trial
Locations (35)
California Research Institute (CRI)
Los Angeles, United States
Omnicure Clinical Research
Doral, United States
Bioresearch Partner
Hialeah, United States
Florida Clinical Trials Group
Plantation, United States
Florida Clinical Trials Group - Tamarac
Tamarac, United States
Morristown Medical Center
Morristown, United States
START New York-Long Island
Lake Success, United States
Memorial Sloan Kettering Cancer Center (MSKCC)
New York, United States
START Dallas Fort Worth
Fort Worth, United States
University of Texas MD Anderson Cancer Center
Houston, United States
GenesisCare North Shore (Oncology)
Saint Leonards, Australia
Calvary Mater Newcastle Hospital
Waratah, Australia
Grampians Health
Ballarat, Australia
Chris O'Brien Lifehouse (Sydney Cancer Centre)
Camperdown, Australia
Oncology Clinics Victoria (OCV) - Cabrini Brighton Hospital
Frankston, Australia
Peninsula and Southeast Oncology (PASO) Medical
Frankston, Australia
Ordensklinikum Linz Elisabethinen
Linz, Austria
Centre Hospitalier Universitaire Brugmann - Victor Horta
Brussels, Belgium
Kuopio University Hospital
Kuopio, Finland
Norddeutsches Studienzentrum fur Innovative Onkologie (NIO) Hamatologisch Onkologische Praxis Eppendorf (HOPE)
Hamburg, Germany
Campus Bio-Medico di Rome University
Rome, Italy
Palmerstone North Hospital
Roslyn, New Zealand
Health New Zealand
Wellington, New Zealand
Oslo University
Oslo, Norway
One Day Med
Szczecin, Poland
GCPMED Sp. z o.o., Centrum Medyczne iMed24
Krakow, Poland
Centrum Terapii Wspolczesnej J.M. Jasnorzewska Spolka Komandytowo-Akcyjna
Lodz, Poland
Hospital de Santa Maria
Lisbon, Portugal
Unidade Local de Saúde (ULS) Loures Odivelas
Loures, Portugal
National Cancer Centre Singapore (NCCS)
Singapore, Singapore
Ajou University School of Medicine & Graduate School of Medicine
Suwon, South Korea
START - Barcelona
Barcelona, Spain
START Rioja - Hospital de San Pedro
Logroño, Spain
NEXT Madrid HUQSM
Madrid, Spain
Hospital Universitario Miguel Servet
Zaragoza, Spain
Trial contact
Ana C Mamede, PharmD
Krishna Kaza
Contact information from ClinicalTrials.gov. Contact in English.
Share this trial
Data from ClinicalTrials.gov. AI-assisted translation, last sync: 9/23/2026.
You can help another person
We fund the Radar, this site, and the development of our Grosz dla Życia fundraising platform from donations and our own resources. Every contribution, even a small one, really helps.